Posted by Michael Wonder on 21 Apr 2022
Revance receives FDA acceptance of BLA resubmission for daxibotulinumtoxinA for injection for glabellar lines
21 April 2022 - PDUFA goal date set for 8 September 2022.
Revance Therapeutics today announced that the U.S. FDA has accepted its biologics license application resubmission for daxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.
